Renaissance Technologies - HAEMONETICS CORP ownership

HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 246 filers reported holding HAEMONETICS CORP in Q3 2021. The put-call ratio across all filers is 1.26 and the average weighting 0.1%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of HAEMONETICS CORP
ValueSharesWeighting
Q3 2023$12,747
+109.7%
142,300
+99.3%
0.02%
+144.4%
Q2 2023$6,079
+1313.7%
71,400
+1273.1%
0.01%
+800.0%
Q1 2023$430
+70.6%
5,200
+62.5%
0.00%
Q4 2022$252
-100.0%
3,200
-92.0%
0.00%
-100.0%
Q2 2022$2,614,000
+87.1%
40,100
+81.4%
0.00%
+50.0%
Q1 2022$1,397,000
-84.8%
22,100
-83.0%
0.00%
-83.3%
Q3 2021$9,162,000
-77.1%
129,785
-78.4%
0.01%
-76.0%
Q2 2021$40,017,000
-71.8%
600,494
-53.1%
0.05%
-71.8%
Q1 2021$142,103,000
-24.1%
1,280,094
-18.8%
0.18%
-12.8%
Q4 2020$187,173,000
+10.9%
1,576,194
-18.5%
0.20%
+20.1%
Q3 2020$168,758,000
-13.9%
1,934,185
-11.6%
0.17%0.0%
Q2 2020$195,938,000
-10.0%
2,187,785
+0.2%
0.17%
-19.9%
Q1 2020$217,696,000
-22.3%
2,184,385
-10.5%
0.21%
-1.9%
Q4 2019$280,335,000
-15.4%
2,439,816
-7.1%
0.22%
-23.2%
Q3 2019$331,357,000
+10.8%
2,626,900
+5.7%
0.28%
+6.5%
Q2 2019$298,973,000
+43.9%
2,484,400
+4.6%
0.26%
+39.2%
Q1 2019$207,826,000
-14.2%
2,375,700
-1.8%
0.19%
-28.7%
Q4 2018$242,081,000
-6.4%
2,419,600
+7.2%
0.26%
-0.4%
Q3 2018$258,550,000
-5.4%
2,256,500
-31.4%
0.27%
+78.5%
Q2 2018$273,178,000
+183.0%
3,289,200
+149.3%
0.15%
+40.6%
Q1 2018$96,535,000
+70.1%
1,319,500
+35.0%
0.11%
+68.3%
Q4 2017$56,750,000
+44.3%
977,100
+11.5%
0.06%
+37.0%
Q3 2017$39,315,000
+8.2%
876,207
-4.7%
0.05%0.0%
Q2 2017$36,323,000
+9.4%
919,800
+12.4%
0.05%0.0%
Q1 2017$33,211,000
-7.7%
818,600
-8.6%
0.05%
-19.3%
Q4 2016$35,987,000
+12.5%
895,200
+1.3%
0.06%0.0%
Q3 2016$31,995,000
+42.0%
883,600
+13.7%
0.06%
+32.6%
Q2 2016$22,534,000
+132.4%
777,300
+180.4%
0.04%
+138.9%
Q1 2016$9,696,000
+58.5%
277,200
+46.1%
0.02%
+38.5%
Q4 2015$6,116,000
-27.2%
189,700
-27.0%
0.01%
-35.0%
Q3 2015$8,403,000
+338.8%
260,000
+461.6%
0.02%
+400.0%
Q2 2015$1,915,000
-49.4%
46,300
-45.1%
0.00%
-50.0%
Q1 2015$3,787,000
+0.8%
84,300
-16.0%
0.01%
-11.1%
Q4 2014$3,757,000
+193.1%
100,400
+173.6%
0.01%
+125.0%
Q3 2014$1,282,000
-83.1%
36,700
-82.9%
0.00%
-77.8%
Q2 2014$7,578,000
-8.5%
214,800
-15.5%
0.02%
-10.0%
Q1 2014$8,285,000
+653.2%
254,226
+874.0%
0.02%
+566.7%
Q4 2013$1,100,000
-88.4%
26,100
-89.0%
0.00%
-87.0%
Q3 2013$9,472,000
-2.1%
237,500
+1.5%
0.02%
-8.0%
Q2 2013$9,672,000233,9000.02%
Other shareholders
HAEMONETICS CORP shareholders Q3 2021
NameSharesValueWeighting ↓
Millrace Asset Group, Inc. 19,264$1,7262.13%
Parkman Healthcare Partners LLC 88,962$7,969,2161.46%
HEARTLAND ADVISORS INC 256,414$24,435,2741.37%
Riverwater Partners LLC 15,553$1,393,2381.27%
KINGDON CAPITAL MANAGEMENT, L.L.C. 111,100$9,952,3381.15%
Lisanti Capital Growth, LLC 78,425$7,025,3121.11%
Aristotle Capital Boston, LLC 311,666$27,919,0540.90%
ROYCE & ASSOCIATES LP 947,550$84,881,5290.86%
CHASE INVESTMENT COUNSEL CORP 18,770$1,6810.84%
Virtus Investment Advisers, Inc. 13,662$1,223,8420.83%
View complete list of HAEMONETICS CORP shareholders